510(k)

K071649: NEONATAL TOTAL GALACTOSE KIT; NEONTAL TOTAL GALACTOSE KIT, MODELS 3029-0010 AND 3029-110B

FDA 510(k) · Wallac OY · decided Aug 7, 2008

Key facts

510(k) number K071649
Device name NEONATAL TOTAL GALACTOSE KIT; NEONTAL TOTAL GALACTOSE KIT, MODELS 3029-0010 AND 3029-110B
Applicant Wallac OY
Product code JIA
Date received Jun 18, 2007
Decision date Aug 7, 2008
Decision Substantially equivalent (SESE)
Submission type Traditional
Review panel Clinical Chemistry
Medical specialty Clinical Chemistry

At a glance

  • 10–99 MAUDE adverse event reports
  • 1–9 Recall events
  • 1–9 UDI device identifiers (GUDID)
  • 1–9 Predicate devices cited
  • 1–9 Later submissions citing this device
  • 1–9 510(k)s with this product code
  • Yes 510(k) summary on file
  • No 510(k) statement on file
  • Not listed On the FDA AI-enabled device list

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

Reading a 510(k)

Decision
SESE means the FDA found the device substantially equivalent to its predicate, so it may be marketed in the United States.
Predicates
Each clearance cites one or more legally marketed devices; the chain of predicates shows where a technology came from.
Product code
The three-letter code sets the device type, class and regulation, and groups competing clearances.
Summary or statement
Applicants file either a 510(k) summary of the safety and effectiveness information or a statement that it is available on request.

About 510(k) premarket notifications

A 510(k) is a premarket submission made to the FDA to demonstrate that a device is substantially equivalent to a legally marketed predicate device.

Source: U.S. Food and Drug Administration (FDA), 510(k) Premarket Notification database · Source date:

Browse all 510(k) premarket notifications